Your browser is no longer supported. Please, upgrade your browser.
Burning Rock Biotech Limited
Index- P/E- EPS (ttm)-1.06 Insider Own0.14% Shs Outstand104.23M Perf Week-11.16%
Market Cap1.36B Forward P/E- EPS next Y-6.45 Insider Trans0.00% Shs Float58.51M Perf Month-15.51%
Income-110.10M PEG- EPS next Q-1.83 Inst Own49.60% Short Float2.84% Perf Quarter-40.22%
Sales77.20M P/S17.58 EPS this Y-109.40% Inst Trans9.16% Short Ratio4.54 Perf Half Y-57.07%
Book/sh3.10 P/B3.95 EPS next Y17.60% ROA-27.20% Target Price27.73 Perf Year-52.92%
Cash/sh2.35 P/C5.22 EPS next 5Y5.10% ROE-31.20% 52W Range11.74 - 39.75 Perf YTD-46.93%
Dividend- P/FCF- EPS past 5Y- ROI-16.70% 52W High-70.20% Beta-
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin72.70% 52W Low0.89% ATR1.41
Employees938 Current Ratio6.50 Sales Q/Q2.20% Oper. Margin- RSI (14)35.65 Volatility13.38% 9.69%
OptionableNo Debt/Eq0.00 EPS Q/Q-33.50% Profit Margin- Rel Volume1.96 Prev Close12.26
ShortableYes LT Debt/Eq0.00 EarningsNov 16 BMO Payout- Avg Volume365.72K Price11.85
Recom1.70 SMA20-19.13% SMA50-21.88% SMA200-50.71% Volume261,714 Change-3.38%
Oct-15-21Resumed Cowen Outperform
Jul-07-20Initiated Cowen Outperform
Nov-17-21 08:15PM  
Nov-15-21 10:21PM  
Nov-04-21 03:06AM  
Nov-03-21 12:00AM  
Aug-31-21 12:00PM  
Aug-03-21 03:00AM  
Aug-02-21 04:00AM  
Jul-26-21 02:15AM  
Jun-11-21 06:49AM  
May-26-21 04:00AM  
May-25-21 06:15AM  
May-19-21 05:06AM  
May-12-21 04:00AM  
Apr-29-21 07:30AM  
Apr-28-21 10:00PM  
Apr-20-21 07:21AM  
Apr-13-21 03:39AM  
Mar-19-21 02:21PM  
Mar-14-21 04:09AM  
Mar-11-21 05:15AM  
Mar-10-21 07:00PM  
Feb-08-21 08:00PM  
Jan-22-21 08:30AM  
Dec-15-20 08:18AM  
Dec-11-20 02:21PM  
Dec-04-20 06:34AM  
Dec-01-20 06:47PM  
Nov-20-20 06:15AM  
Nov-15-20 08:00PM  
Oct-29-20 11:21PM  
Oct-20-20 09:30PM  
Oct-06-20 07:00AM  
Oct-01-20 04:05PM  
Sep-12-20 10:15AM  
Sep-03-20 02:09AM  
Aug-11-20 12:38AM  
Jul-20-20 09:52PM  
Jun-28-20 09:00PM  
Jun-22-20 06:30AM  
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer. In addition, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone and BeiGene. The company was founded in 2014 and is headquartered in Guangzhou, China.